You act as a paraphrase tool. Your role involves understanding the provided text…
- User
System: You act as a paraphrase tool. Your role involves understanding the provided text and then providing a positive example that keeps the original meaning of the text unchanged while using synonyms, interchanging, adding or removing words or sentences, and then provide a negative example where the meaning of the original text is at its opposite. Output your response with the following format : Positive : Negative :
User: We own intellectual property, including patents, patent applications, technology, trade secrets and know-how in the U.S. and other countries. The protection of patents, designs, trademarks and other proprietary rights that we own or license is critical to our success and competitive position. We consider the overall protection of our patents and other intellectual property rights to be of material value and act to protect these rights from infringement. We seek to protect our technology by, among other methods, filing and prosecuting U.S. and foreign patents and patent applications with respect to our technology and products and their uses. The focus of our patent strategy is to secure and maintain intellectual property rights to technology for our program in neurodegeneration. Simufilam was discovered and designed in-house and was characterized by our academic collaborators during research activities that were conducted from approximately 2008 to date. SavaDx is being developed in-house with outside collaborators. We own exclusive, worldwide rights to drug and diagnostic assets and related technologies, without royalty obligations to any third party. Our patent protection with respect to simufilam and use of simufilam for Alzheimer’s disease and other neurodegenerative diseases currently runs through 2039 and includes seven issued U.S. patents. In addition, we have patent protection with respect to simufilam for use in treating certain cancers that runs through 2034. Our patent estate further includes patents and patent applications for related Assistant:
- Assistant
Positive: We possess intellectual properties, such as patents, patent filings, technologies, trade secrets, and expertise both within the U.S. and internationally. Safeguarding our patents, designs, trademarks, and other proprietary rights, whether owned or licensed, is essential for our thriving and competitive stance. We view the comprehensive protection of our patents and intellectual property rights as significantly valuable and actively defend these rights from infringement. Our approach to safeguarding our technology includes submitting and pursuing patents and patent applications in the U.S. and globally concerning our technology, products, and their applications. Our patent strategy centers on obtaining and preserving intellectual property rights for our neurodegeneration program. Simufilam was internally discovered and designed, with academic collaborators characterizing it through research that has been ongoing since approximately 2008. SavaDx is being developed internally with external collaboration. We hold exclusive, global rights to our drug and diagnostic assets and related technologies, free from any royalty obligations to third parties. Our patent protection concerning simufilam and its use for Alzheimer's and other neurodegenerative diseases is valid until 2039, including seven granted U.S. patents. Furthermore, we have patent protection covering the use of simufilam for treating various cancers, extending until 2034. Our patent portfolio also contains additional patents and patent applications.
Negative: We do not own any intellectual property, such as patents or technology, in the U.S. or elsewhere. The protection of patents, designs, trademarks, and other proprietary rights is irrelevant to our success and competitive position. We think the protection of our patents and intellectual property rights is unimportant and take no action to prevent infringement. We do not prioritize patenting our technology nor do we actively pursue patent filings for our products. Our efforts in securing intellectual property rights are not focused on the technology related to our neurodegeneration program. Simufilam was neither discovered nor designed in-house, and there has been no characterization by our academic partners. SavaDx is not developed internally. We do not possess exclusive rights to our drug and diagnostic assets, and we are obligated to pay royalties to third parties. Our patents for simufilam and its use for Alzheimer's extend only briefly past the current year, with few or no issued U.S. patents. Additionally, we lack patent coverage for the use of simufilam in treating cancers. Our patent estate is minimal and unprotected.